The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2020

Filed:

Apr. 07, 2016
Applicants:

Shire Human Genetic Therapies, Inc., Lexington, MA (US);

The Regents of the University of Colorado, a Body Corporate, Denver, CO (US);

Inventors:

Dennis Keefe, Lexington, MA (US);

Steven Abman, Aurora, CO (US);

Gregory Seedorf, Aurora, CO (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A23L 33/10 (2016.01); A61K 31/07 (2006.01); A61K 31/56 (2006.01); A61K 33/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A23L 33/10 (2016.08); A61K 9/007 (2013.01); A61K 9/0012 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0073 (2013.01); A61K 31/07 (2013.01); A61K 31/56 (2013.01); A61K 33/00 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A23V 2002/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention provides, among other things, methods and compositions for treating chronic lung disorders, in particular, bronchopulmonary dysplasia (BPD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to BPD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of BPD is reduced in intensity, severity, or frequency, or has delayed onset.


Find Patent Forward Citations

Loading…